Piromelatine is under clinical development by Neurim Pharmaceuticals and currently in Phase III for Dementia Associated With Alzheimer’s Disease. According to GlobalData, Phase III drugs for Dementia Associated With Alzheimer’s Disease have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Piromelatine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Piromelatine overview
Piromelatine (Neu-P11) is under development for the treatment of dementia associated with Alzheimer's disease. It is administered orally. It acts on melatonin MT1/2/3, serotonin 5-HT-1A/1D, 5-HT2B receptors, P2X3, TRPV1 and Nav1.7 channels. It is a new chemical entity (NCE). It was also under development for the treatment of hypertension and visceral pain of abdominal origin, ocular hypertension, open-angle glaucoma, primary and comorbid insomnia.
See Also:
Neurim Pharmaceuticals overview
Neurim Pharmaceuticals (Neurim) is a neuroscience drug discovery and development company that offers drugs for the central nervous system primarily in age-related disorders. The company offers products such as circadin that is used in insomnia treatment. Neurim offers pediatric prolonged-release melatonin, piromelatine, NEU-P12 and NEU-240. The company also manufactures preclinical phase products. It offers treatments for other therapeutic areas such as Parkinson’s disease, and asthma or chronic obstructive pulmonary disease. The company has its presence in Israel and Switzerland. Neurim is headquartered in Tel Aviv, Israel
For a complete picture of Piromelatine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
